Stock Analiz

ARS Pharmaceuticals, Inc. SPRY

Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026

$3.89Market cap $391M
Open the interactive analysis →

ARS Pharmaceuticals, Inc. (SPRY) is a healthcare company listed in the US with a market value of about $391M. In the twelve months to September 30, 2026 it had revenue of $122M and net income of -$200M, a net margin of -163.6%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -31%.

About ARS Pharmaceuticals

ARS Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $6M in 2021 to $84M in 2025, growth of about 97.8% a year. It was profitable in 1 of the last 6 years in our data. Its share count rose by 147% over three years (dilution for shareholders). It spends 16% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.2
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-46.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-5.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-36879.5%
ROIC (5-yr avg.)-31.4%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$122M$84M$89M$30000$1M$6M—
Net income-$200M-$171M$8M-$54M-$35M-$20M-$33M
Free cash flow-$183M-$171M$13M-$59M-$40M-$18M-$32M
EPS (diluted)$-2.02$-1.74$0.08$-0.57$-0.87$-0.70$-11.33
Net margin-163.6%-203.3%9.0%-181200.0%-2635.4%-367.6%—
ROIC—-85.2%-1.2%-29.2%-10.3%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $17.00, 337% above the current price; targets range from $14.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.87 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does ARS Pharmaceuticals pay a dividend?

Not currently.

Is ARS Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. ARS Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.